MHC class II–restricted ragweed allergen–specific T-cell receptor (Ragweed-specific TCR)

MHC class II–restricted ragweed allergen–specific T-cell receptors (TCRs) are specialized antigen receptors expressed on the surface of CD4+ T lymphocytes that recognize peptide fragments of ragweed pollen allergens, most notably Amb a 1. These peptides are presented by specific Major Histocompatibility Complex (MHC) class II molecules, such as HLA-DRB1*15:01, on the surface of antigen-presenting cells. The interaction between the TCR and the allergen-MHC complex is a critical early event in the allergic cascade, leading to the activation and expansion of Th2 cells. These Th2 cells subsequently drive the production of allergen-specific IgE and the recruitment of inflammatory cells like eosinophils and mast cells, resulting in the symptoms of allergic rhinitis and asthma. Therapeutic strategies targeting these receptors include allergen-specific immunotherapy (AIT) and peptide-based vaccines, which aim to reprogram the immune system toward a state of tolerance. By delivering controlled doses of the allergen or its T-cell epitopes, these treatments seek to induce T-cell anergy or promote the development of regulatory T cells that suppress the allergic response.

Other names

Ragweed allergen-specific T-cell receptorAmb a 1-specific T-cell receptorAllergen-specific TCRMHC-II restricted ragweed TCR

Allergen-specific immunotherapy (AIT) and peptide-based therapies target these receptors to induce immune tolerance through mechanisms such as T-cell anergy, the induction of regulatory T cells (Tregs), or immune deviation from a Th2-dominated response to a Th1 or regulatory profile.